Press release
Chemotherapy-Induced Febrile Neutropenia Market valued at USD 2.95 billion in 2024 and is projected to reach USD 5.12 billion by 2034
Chemotherapy-Induced Febrile Neutropenia Market
The global CIFN market was valued at USD 2.95 billion in 2024 and is projected to reach USD 5.12 billion by 2034, growing at a CAGR of 5.7% during the forecast period.
Download Full PDF Sample Copy of Market Report
https://exactitudeconsultancy.com/request-sample/71301
Market Dynamics
Key Drivers
• Rising global incidence of cancer, increasing the number of patients receiving chemotherapy.
• High prevalence of chemotherapy regimens causing myelosuppression, elevating the risk of febrile neutropenia.
• Increasing adoption of G-CSFs such as filgrastim, pegfilgrastim, lenograstim, and biosimilars.
• Shift toward outpatient cancer care, increasing the need for prophylactic neutropenia management.
• Growing hospital admission rates for febrile neutropenia cases, driving supportive therapy demand.
• Rising awareness regarding treatment guidelines such as NCCN, ASCO, and ESMO, encouraging prophylactic use of G-CSF.
Restraints
• High cost of branded biologics such as long-acting pegfilgrastim.
• Side effects associated with repeated G-CSF administration.
• Limited access to advanced cancer centers in low-income regions.
• Slower adoption of biosimilars in some markets due to physician hesitation.
Opportunities
• Rapid global expansion of biosimilar G-CSFs, reducing treatment costs.
• Development of novel long-acting G-CSF formulations with improved safety and dosing convenience.
• Artificial intelligence-enabled tools to predict neutropenia risk in cancer patients.
• Growth of oncology networks and infusion centers across Asia-Pacific.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71301/chemotherapy-induced-febrile-neutropenia-market
Market Segmentation
By Drug Class
• Granulocyte Colony-Stimulating Factors (G-CSFs)
o Filgrastim
o Pegfilgrastim
o Lenograstim
o Tbo-filgrastim
o Biosimilar G-CSFs
• Antibiotics
• Antifungals & Antivirals
• Other Supportive Drugs
By Treatment Type
• Prophylactic Treatment
• Curative Treatment (Therapeutic)
By End User
• Hospitals
• Specialty Cancer Centers
• Home Healthcare
• Retail & Online Pharmacies
By Geography
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa
Regional Insights
North America
North America held the largest share of the market in 2024, valued at USD 1.05 billion, driven by high adoption of G-CSFs, strong cancer treatment infrastructure, and widespread use of biosimilars. The U.S. continues to dominate due to early approvals and a large chemotherapy patient population.
Europe
Europe accounted for USD 780 million in 2024, supported by national cancer care programs, high biosimilar penetration, and standardized FN prevention guidelines. Germany, France, Italy, and the UK are key countries driving market demand.
Asia-Pacific
Asia-Pacific is the fastest-growing region, projected to grow at a CAGR of 7.1%. Rising cancer prevalence, increasing chemotherapy utilization, and growing biosimilar adoption in India, China, South Korea, and Japan are major growth contributors.
Latin America & Middle East/Africa
These regions together generated USD 320 million in 2024. Growth is supported by expanding oncology care access, improving insurance coverage, and increased diagnosis of cancer-related complications.
Get Your Exclusive Offer with up to 10% Discount
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71301
Competitive Landscape
Key companies in the Chemotherapy-Induced Febrile Neutropenia market include:
• Amgen Inc.
• Pfizer Inc.
• Novartis AG (Sandoz)
• Teva Pharmaceutical Industries Ltd.
• Dr. Reddy's Laboratories
• Biocon Biologics
• Intas Pharmaceuticals
• Mylan/Viatris
• Hospira
• Fresenius Kabi
Leading manufacturers are focusing on long-acting formulations, cost-effective biosimilars, and expanded oncology support programs.
Recent Developments
• Approval and global launch of multiple biosimilar pegfilgrastim products.
• New real-world evidence validating long-acting G-CSFs as first-line prophylaxis.
• Growth in home-injection devices and auto-injectors improving patient convenience.
• Increasing adoption of risk stratification tools for personalized FN prevention.
Future Outlook
The CIFN market will continue growing steadily as global cancer incidence rises and supportive oncology care becomes more standardized. Future growth will be shaped by:
• Strong uptake of biosimilar G-CSFs lowering treatment costs
• Development of next-generation neutropenia prevention therapies
• Expansion of oncology infusion centers in emerging regions
• Integration of AI-based neutropenia prediction models in chemotherapy planning
By 2034, the global CIFN market will reach USD 5.12 billion, driven by both technological advancements and wider global cancer treatment access.
This report is also available in the following languages : Japanese (化学療法誘発性発熱性好中球減少症市場), Korean (화학요법으로 유발된 열성 호중구감소증 시장), Chinese (化疗诱发发热性中性粒细胞减少症市场), French (Marché de la neutropénie fébrile induite par la chimiothérapie), German (Markt für Chemotherapie-induzierte febrile Neutropenie), and Italian (Mercato della neutropenia febbrile indotta dalla chemioterapia), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71301
Our More Reports:
Sarcoidosis Market
https://exactitudeconsultancy.com/reports/71350/sarcoidosis-market
Anti-Glomerular Basement Membrane Market
https://exactitudeconsultancy.com/reports/71352/anti-glomerular-basement-membrane-market
Peanut Allergy Market
https://exactitudeconsultancy.com/reports/71354/peanut-allergy-market
Cytomegalovirus (CMV) Infections Market
https://exactitudeconsultancy.com/reports/71356/cytomegalovirus-cmv-infections-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chemotherapy-Induced Febrile Neutropenia Market valued at USD 2.95 billion in 2024 and is projected to reach USD 5.12 billion by 2034 here
News-ID: 4310889 • Views: …
More Releases from Exactitude Consultancy
Liposarcoma Market is projected to reach USD 2.14 billion by 2034
The global Liposarcoma Market was valued at USD 1.28 billion in 2024 and is projected to reach USD 2.14 billion by 2034, growing at a CAGR of 5.3% during 2025-2034. Growth is driven by increasing incidence of soft-tissue sarcomas, rising adoption of molecularly targeted therapies, improvements in sarcoma pathology and genetic profiling, and expanding access to advanced radiation and surgical oncology services.
Download Full PDF Sample Copy of Market Report @…
Arteriovenous Fistula (AVF) Market was Valued at USD 1.18 billion in 2024 and is …
Arteriovenous Fistula (AVF) Market Overview (With Market Size & CAGR)
The Arteriovenous Fistula (AVF) Market is witnessing steady global growth driven by rising end-stage renal disease (ESRD) cases and the increasing global dialysis population. AVF remains the preferred vascular access type for hemodialysis due to its superior long-term patency, reduced infection risk, and lower maintenance costs compared to grafts and catheters.
The global AVF market was valued at USD 1.18 billion in…
Larynx Cancer Market is projected to reach USD 17.86 billion by 2034
The global Larynx Cancer Market was valued at USD 10.41 billion in 2024 and is projected to reach USD 17.86 billion by 2034, growing at a CAGR of 5.6% from 2025 to 2034. Market growth is driven by rising incidence of head and neck cancers, increasing adoption of immunotherapies and targeted therapies, advancements in minimally invasive surgical techniques, and heightened awareness of early-stage detection through laryngoscopy and imaging tools.
Download Full…
Anemia in Elderly Market was valued at USD 6.8 billion and is projected to reach …
Anemia in Elderly Market Overview
The Anemia in Elderly Market is experiencing sustained growth due to the rapidly expanding geriatric population and rising chronic disease burden worldwide. In 2024, the global market was valued at USD 6.8 billion and is projected to reach USD 11.4 billion by 2034, growing at a CAGR of 5.2% during the forecast period. Aging demographics, improved diagnostic capabilities, and advancements in anemia therapeutics are key forces…
More Releases for Febrile
Febrile Seizures Market Business Growth and Industry Development by 2034
The Febrile Seizures Market Is Set To Grow At An Estimated CAGR Of 6.2% From 2025 To 2034, Rising From $3.2 Billion In 2024 To $5.6 Billion By 2034.
On April 10, 2025, Exactitude Consultancy., Ltd. released a research report titled "Febrile Seizures Market" This report offers a new perspective on the Febrile Seizures Market covering an extensive range of aspects including market overview, expenditure analysis, import trends, segmentation, key players,…
Febrile Seizures Market: Global Industry Analysis and Forecast (2024-2030)
Febrile Seizures Market to reach USD 1573.16 Mn at a CAGR of 4.5 percent over the forecast period
The Febrile Seizures Market was valued at USD 1156 Million in 2023, with revenue expected to grow at a CAGR of 4.5%, reaching nearly USD 1573.16 Million by 2030.
To access more details regarding this research, visit the following webpage:https://www.stellarmr.com/report/Febrile-Seizures-Market/2064
Febrile Seizures Market Scope and Research Methodology
The Febrile Seizures Market report employs an extensive research…
Febrile Seizures Market Anticipates Growth in Forecast Period 2024-2031
The "Febrile Seizures Market" is a dynamic and rapidly evolving sector, with significant advancements and growth anticipated by 2031. Comprehensive market research reveals a detailed analysis of market size, share, and trends, providing valuable insights into its expansion. This report delves into segmentation and definition, offering a clear understanding of market components and drivers. Employing SWOT and PESTEL analyses, the study evaluates the market's strengths, weaknesses, opportunities, and threats, alongside…
Acute Febrile Neutrophilic Dermatosis Market - Defending Skin Integrity with Adv …
Newark, New Castle, USA - new report, titled Acute Febrile Neutrophilic Dermatosis Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Acute Febrile Neutrophilic Dermatosis market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Acute Febrile Neutrophilic Dermatosis market. The report offers…
Acute Febrile Neutrophilic Dermatosis Market Insights, Forecast to 2031
Acute Febrile Neutrophilic Dermatosis Market 2021 by Technology, Manufacturers, Regions, Type, and Application, Forecast guide to light the excellent analysis on the market synopsis. The report offers a primary focus on important factors in the global Acute Febrile Neutrophilic Dermatosis industry. The report includes perceptive information about gross revenue, cost, value, capacity, pricing, and profit margins concerning historical analysis and forecast estimation for the 2021 to 2031 time period. It…
Febrile Neutropenia Market Significantly Stepping towards the Success Till 2027
Alpha-2 antiplasmin, commonly known as a plasmin inhibitor, is a glycoprotein made by the liver, kidneys, and other bodily organs. Alpha-2 Antiplasmin is a serine protease inhibitor belonging to the Serpin superfamily that is responsible for the breakdown of fibrin clots and the inhibition of fibrinolysis. Due to an increase in fibrinolysis, a lack of Alpha 2 antiplasmin causes bleeding problems. Internal bleeding is caused by a congenital lack of…
